No Data
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
Apellis Pharmaceuticals Initiated at Equal-Weight by Morgan Stanley
Morgan Stanley Initiates Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $31
Neutral Stance on Apellis Pharmaceuticals Amid Competitive Uncertainties and Market Stability
Scotiabank Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Apellis Pharmaceuticals Up Nearly 16%, On Pace for Largest Percent Increase Since August 2023 -- Data Talk
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
been hot today but that's getting into buying range for me..... EBS middle size company that got a new CEO last year completely changed things around since for EBS. take a look at who owns EBS and how much together. this small float is trading around 50% since half or more is already bought up by insiders or tutes
